Maximizing Kasai portoenterostomy in the treatment of biliary atresia: Medical and surgical options by Davenport, Mark & Grieve, Andrew
FORUM
865  November 2012, Vol. 102, No. 11  SAMJ
REVIEW
Maximising Kasai portoenterostomy in the treatment of 
biliary atresia: Medical and surgical options
A Grieve, M Davenport
Ladd1 described his experience of operating on newborn infants with 
surgical jaundice at Boston Children’s Hospital. Although it is unclear 
how many of his cases had genuine biliary atresia (BA), his results were 
remarkable, with 6/11 cases draining bile. Unfortunately, later reports 
identified most cases of BA as ‘uncorrectable’, with an inevitable dismal 
outcome despite many desperate surgical manoeuvres.2,3 Those surgical 
pioneers recognised that no matter how high the level of biliary 
dissection, it was not possible to identify any bile-containing structure 
to fashion any kind of conventional biliary anastomosis. 
Kasai4 published his first report in the Japanese surgical journal 
Shujitsu in 1959. He recognised, albeit accidentally, that the apparently 
solid proximal biliary remnant contained microscopic biliary 
channels which retained a communication with the intrahepatic bile 
duct system. Therefore, if enough of these could be exposed in the 
porta hepatis and be drained into a Roux loop, then sufficient bile 
flow could be restored and jaundice would recede. 
The results in ‘uncorrectable’ BA were greeted with scepticism 
in the West, and it was not until the 1970s that the procedure 
was taken up by institutions in the USA and western Europe. Our 
experience with the Kasai procedure at King’s College Hospital 
dates from this era.5 Nevertheless, what Kasai performed in the 
1950s and 1960s is not necessarily what we would recognise today. 
His original technique, while reaching the surgical plane flush with 
the liver capsule, does not attempt to go beyond a fairly narrow oval 
within the bifurcation of the portal vein (5 mm diameter), and uses 
a short Roux loop (25 - 30 cm) with a relatively crude anastomosis 
(5/0 surgical catgut).6 Later, authors sought to increase the area 
exposed by dissecting into the Rex fossa around the umbilical point 
(junction with left portal vein) and around the bifurcation of the 
right vascular pedicle.7,8 This more extended approach leaves a 
denuded area approaching 20 x 10 mm, to be incorporated into a 
longer (40 - 50 cm) Roux loop (Fig. 1). 
The only other element of the operation which changed, but 
was subsequently reverted to the original, was the design and 
configuration of the Roux loop. It became fashionable to open 
the loop to the skin as a stoma and then re-feed the bile back 
in again in an attempt to reduce the incidence of post-operative 
cholangitis.9 Other modifications with the same objective included 
the creation of ‘valves’ within the loop.10 Despite initial acceptance 
of theoretical benefit, neither manoeuvre has any advantage to the 
standard long Roux-en-Y limb. About 20% of cases have a patent 
common bile duct and gallbladder, leading to a mucocele, which 
can be used as the conduit with the transected porta hepatis (i.e. a 
portocholecystostomy). This abolishes the risk of cholangitis, but 
bile drainage is more tenuous and a much higher revision rate leads 
to failure.11 Efforts to use the appendix as a conduit have also been 
discarded with time. 
Biliary atresia (BA) remains one of the most challenging conditions 
in paediatric surgery. It has several possible causes, resulting in 
a range of different clinical scenarios. The current therapeutic 
approach is almost entirely surgical with an initial attempt to 
restore bile flow and preserve the native liver using a Kasai-type 
portoenterostomy. Liver transplantation (cadaveric or living donor) 
is usually reserved for failure or for infants presenting late with end-
stage cirrhosis. The role of adjuvant medical therapy is unclear and 
evidence of benefit is lacking. Nonetheless, the use of post-operative 
steroids, prophylactic antibiotics and choleretic agents such as 
ursodeoxycholic acid is common. Ideally, the entire pathway should 
be complementary and seamless with few infants dying of end-stage 
liver disease or uncorrectable associated congenital malformations. 
Experience from high-volume centres suggests that clearance of 
jaundice can be achieved in 50 - 60% of infants, with 10-year native 
liver and real survival rates of 45% and 90%, respectively.
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Fig. 1. Schematic illustration of extended Kasai portoenterostomy at the 
level of porta hepatis – from bifurcation of the right vascular pedicle to the 
junction of the umbilical vein and left portal vein in the Rex fossa. Arteries 
have been removed for clarity.
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The advent of minimally invasive surgery and laparoscopic 
techniques probably reached its apogee with a successful laparoscopic 
Kasai portoenterostomy (KPE) by a Brazilian team in 2002.12 Several 
small-series case reports followed, together with a prospective trial 
from Hannover, Germany.13-15 Most pioneers came to recognise that, 
while possible, the laparoscopic technique was sufficiently different to 
lead to poorer outcomes.15,16 Isolated centres in China, Japan and South 
America still offer this technique, but most larger centres have reverted. 
What would constitute an open radical extended KPE today? The 
principles include a radical dissection within the porta hepatis to 
separate the proximal biliary remnant (and any lymphatic efferents) 
from the right and left portal vein and the hepatic arteries. Usually, 
small veins from the confluence of the portal vein are divided, 
exposing the caudate lobe as the posterior limit. The Rex fossa on 
the left side can be opened by dividing the isthmus of liver tissue 
connecting segments III and IV exposing the junction of umbilical 
vein with left portal vein. This triangular, pyramidal biliary remnant 
is then transected flush with the capsule, starting in the gallbladder 
fossa. It extends on the right side to incorporate a small triangular 
area between the anterior and posterior right vascular pedicle and on 
the left to the umbilical point. Controversy remains as to how best 
to expose the porta hepatis to achieve these goals. Since the 1970s, 
the large centres in London and Paris have advocated dislocation of 
the liver outside of the abdominal cavity by dividing the ligaments. 
Others advocate division of the left triangular ligament, extracting 
only the left lobe to achieve a similar objective. Others leave the liver 
within the peritoneal cavity, but sling the vascular pedicles to aid 
portal dissection. 
KPE, as described here, should be associated with clearance of 
jaundice (to normal) in 50 - 60% of infants.5, 17 
Key variables in outcome 
BA should not be considered a single disease entity with a predictable 
natural history and stereotypical response to surgery. This aetiological 
heterogeneity is complex and our broad classification which seeks to 
categorise syndromic BA and cystic BA as examples of developmental 
BA and cytomegalovirus (CMV)-IgM-positive BA as a clinically 
defined virus-associated BA, still leaves many cases of isolated BA 
with no obvious definable aetiology.18 
However, compared with isolated BA, infants with syndromic BA 
splenic malformation (BASM) respond less well to KPE and have a 
poorer overall outcome with a higher risk of death.5,19 By contrast, 
higher proportions of infants with cystic BA (usually type 1 and 2) 
clear their jaundice after KPE and have a better long-term outcome 
(Fig. 2).20,21 The outcome of these 2 types of developmental BA has 
a marked relationship to the age at which the KPE is performed. 
This is not seen so clearly in isolated BA. In our age-cohort analysis 
of infants aged up to about 100 days at King’s College Hospital, we 
could not predict outcome (by clearance of jaundice or need for 
transplantation by 2 years) simply on the grounds of age. Certainly, 
no ‘cut-offs’ at 6, 8, or 10 weeks were evident.22
The poorest outcome and highest risk of death is in the group of 
infants with CMV-IgM-positive-associated BA. These infants are 
usually older at presentation and at time of KPE, are more jaundiced 
and have a pronounced hepatic inflammatory reaction with a higher 
degree of fibrosis. Consequently, their chance of clearance of jaundice 
following KPE is much lower and their need for transplantation 
correspondingly greater.23 
Peri-operative regimens
Given adequate uncomplicated surgery exposing enough ductules, 
the question is: can more be done to improve the chances of eventual 
success? Medical management and perhaps pharmacology may help 
in 4 potential areas.
Bile drainage
Change of stool colour is evident in most cases in the first week post 
KPE; failure is inevitable if this does not occur. While the early return 
and degree of bile flow is related to anatomical factors evident and only 
correctable at surgery, there may be a role for other choleretic agents. 
The efficacy of corticosteroids, which have been used for over 
30 years post KPE, remains unknown. Despite this, about 50% of 
infants with BA treated in the United States of America receive post-
operative steroids.24 The problem is one of scale: BA is rare and few 
centres see more than 5 new cases per year. This is compounded by 
surgeon and disease variation, leaving only small cohorts to analyse.25 
A meta-analysis failed to find evidence of effect.26 A randomised 
placebo-controlled trial from 2 centres in the United Kingdom 
retrospectively reviewed low-dose prednisolone treatment (starting 
at 2 mg/kg/day) in 73 infants.27 The study showed early biochemical 
benefit (reduced 1-month bilirubin), but no effect on ultimate 
outcome (need for transplantation, etc.). Further evidence from one 
of the centres using a higher dose of prednisolone (5 mg/kg/day) 
showed continued biochemical benefit, resulting in an increased 
proportion clearing jaundice (Table 1).
Ursodeoxycholic acid (UDCA) has been used in adult cholestatic 
diseases, such as primary biliary cirrhosis and primary sclerosing 
cholangitis, with evidence of benefit. It appears to increase choleresis, 
with protection of cholangiocytes and hepatocytes.28 A crossover trial 
from France assessed the effect of UDCA (25 mg/kg/day in 3 divided 
doses) on liver function in children more than 1 year post KPE in a 
discontinuation/re-introduction fashion. Sixteen children with BA all 
cleared their jaundice.29 Six months after ceasing UDCA treatment, 
1 child worsened clinically with recurrence of jaundice, and all 
but 2 had significant worsening of their liver enzymes. On UDCA 
re-introduction, their biochemistry improved. 
Other agents such as phenobarbital and the bile acid sequestrant, 
cholestyramine, have been studied in a small randomised trial in 
France, with no significant benefit.30 
Prevention and treatment of cholangitis
Cholangitis may occur in children with some restoration of bile flow, 
typically in the first 2 years post KPE. Early use of potent intravenous 
(IV) antibiotics effective against gram-negative organisms remains the 
Fig. 2. BA outcome by clinical variant. Actuarial (Kaplan-Meier) native 
liver survival curves following Kasai portoenterostomy (N=260) divided 
by clinical variant from King’s College Hospital, London (1999 - 2010). 
Cystic = cystic biliary atresia; Isolated = isolated biliary atresia; Anomaly = 
biliary atresia splenic malformation; CMV = cytomegalovirus-IgM-positive-
associated biliary atresia.
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agreed first-line treatment, but there is controversy about the value of 
any published prophylactic regimen. Some centres insert a Hickman 
line and administer IV antibiotic for 4 - 6 months, while others do not 
administer anything.5
Limitation of hepatic fibrosis
Unlike many cholestatic conditions presenting in infancy, BA is 
characterised by relatively early aggressive hepatic fibrosis and, 
ultimately, cirrhosis that leads to life-threatening portal hypertension 
and the early need for transplantation.31 Modulation of this biological 
process would have immense benefit, but seems elusive and far distant. 
Asian centres routinely prescribe the Chinese herb Inchinko- to; 
claimed benefits include inhibition of apoptosis and liver fibrosis,32 
but real evidence of benefit remains unpublished.
Nutritional management 
BA infants are nutritionally compromised with deficits in protein 
metabolism, low muscle and liver stores of glycogen, obvious fat 
malabsorption, key deficiencies in fat-soluble vitamins (D, A, K and 
E) and, if cirrhotic, low serum and storage levels of zinc and selenium. 
Medical and dietetic attendants must maximise nutritional potential 
and maintain normal growth and development with sub-optimal liver 
and bile flow. This usually involves changing to a more appropriate 
formula (e.g. Caprilon (Nutricia)) with higher medium triglyceride 
levels) and regular parenteral vitamin supplementation. Early initiation 
of overnight naso-gastric feeding also helps to maintain effective calorie/
protein intake, which becomes crucial in the failing liver listed for 
transplantation, where outcome is directly related to nutritional status.33
Benchmark of outcomes in BA
KPE remains an important element in the strategic management 
of the infant with BA. In historical series, it was the only solution 
available. The Sendai (Japan) series reflecting Kasai’s experience is a 
good example of surgical evolution.34 This showed 10-year survival 
rates of 10% for the first 63 patients treated from 1953 to 1967, 27% 
for 44 cases from 1968 to 1972, and 48% for 61 cases from 1973 to 
1977. In addition, not all were jaundice-free, with major problems 
with cholestasis and portal hypertension. By comparison, in our 
recent experience in England and Wales, where liver transplantation 
is available to all regardless of status or income, overall 10-year 
survival was about 90% with native liver survival of 46%.17 Over 
95% of those with their own livers are jaundice-free and have a good 
expectation of normal life. In England and Wales over the past 12 
years, resources and expertise have been concentrated, which is 
probably the most important aspect of maximising KPE potential.
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Table 1. Single surgeon experience (2000 - 2011) with 145 infants (aged <70 days at time of KPE) with isolated BA*
 
Regimen
Clearance of jaundice (<20 μmol/l)
n (%)
Not cleared (>20 μmol/l)
n (%)
No steroid 45 (49.4) 46 (50.6)
Low† (starting 2 mg/kg/day) 11 (61.1) 7 (38.9)
High† (starting 5 mg/kg/day) 24 (66.6) 12 (23.4)
KPE = Kasai portoenterostomy; BA = biliary atresia.
*No steroids or placebo (n=91), low dose (starting at 2 mg/kg/day prednisolone) (n=18), and high dose (starting at 5 mg/kg/day) (n=36).  
†X2 test: steroids v. no steroids (p=0.047).
